SAFER-ROP: Updated protocol for anti-VEGF injections for retinopathy of prematurity

Kinley D. Beck; Effie Z. Rahman; Anna Ells; Kamiar Mireskandari; Audina M. Berrocal; C. Armitage Harper

doi:10.3928/23258160-20200702-05

SAFER-ROP: Updated protocol for anti-VEGF injections for retinopathy of prematurity

Kinley D. Beck, Effie Z. Rahman, Anna Ells, Kamiar Mireskandari, Audina M. Berrocal, C. Armitage Harper

Ophthalmology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

BACKGROUND AND OBJECTIVE: To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP). MATERIALS AND METHODS: SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/ antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser). RESULTS: No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review. CONCLUSION: This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection.

Original language	English (US)
Pages (from-to)	402-406
Number of pages	5
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	51
Issue number	7
DOIs	https://doi.org/10.3928/23258160-20200702-05
State	Published - Jul 2020

ASJC Scopus subject areas

Surgery
Ophthalmology

Access to Document

10.3928/23258160-20200702-05

Cite this

@article{d04ef00f60414d79a2dd875f93f0d44a,

title = "SAFER-ROP: Updated protocol for anti-VEGF injections for retinopathy of prematurity",

abstract = "BACKGROUND AND OBJECTIVE: To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP). MATERIALS AND METHODS: SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/ antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser). RESULTS: No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review. CONCLUSION: This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection.",

author = "Beck, {Kinley D.} and Rahman, {Effie Z.} and Anna Ells and Kamiar Mireskandari and Berrocal, {Audina M.} and {Armitage Harper}, C.",

note = "Publisher Copyright: {\textcopyright} 2020 Beck, Rahman, Ells, et al.; licensee SLACK Incorporated.",

year = "2020",

month = jul,

doi = "10.3928/23258160-20200702-05",

language = "English (US)",

volume = "51",

pages = "402--406",

journal = "Ophthalmic Surgery",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "7",

}

TY - JOUR

T1 - SAFER-ROP

T2 - Updated protocol for anti-VEGF injections for retinopathy of prematurity

AU - Beck, Kinley D.

AU - Rahman, Effie Z.

AU - Ells, Anna

AU - Mireskandari, Kamiar

AU - Berrocal, Audina M.

AU - Armitage Harper, C.

PY - 2020/7

Y1 - 2020/7

N2 - BACKGROUND AND OBJECTIVE: To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP). MATERIALS AND METHODS: SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/ antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser). RESULTS: No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review. CONCLUSION: This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection.

AB - BACKGROUND AND OBJECTIVE: To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP). MATERIALS AND METHODS: SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/ antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser). RESULTS: No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review. CONCLUSION: This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection.

UR - http://www.scopus.com/inward/record.url?scp=85088682251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088682251&partnerID=8YFLogxK

U2 - 10.3928/23258160-20200702-05

DO - 10.3928/23258160-20200702-05

M3 - Article

C2 - 32706898

AN - SCOPUS:85088682251

VL - 51

SP - 402

EP - 406

JO - Ophthalmic Surgery

JF - Ophthalmic Surgery

SN - 2325-8160

IS - 7

ER -

SAFER-ROP: Updated protocol for anti-VEGF injections for retinopathy of prematurity

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this